Neuroprotection and CD131/GDNF/AKT Pathway of Carbamylated Erythropoietin in Hypoxic Neurons

Molecular Neurobiology

Volumn 54, Issue 7, 2017, Pages 5051-5060

  Ding, Jing ^a   Wang, Jing ^a   Li, Qin Ying ^b   Yu, Jie Zhong ^c   Ma, Cun Gen ^c   Wang, Xin ^a   Lu, Chuan Zhen ^b   Xiao, Bao Guo ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANXI DATONG UNIVERSITY   (China)

Author keywords

Carbamylated erythropoietin; CD131; Glial cell derived neurotrophic factor; Neuroprotection

Indexed keywords

CD131 ANTIGEN; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; PROTEIN KINASE B; CARBAMYLATED ERYTHROPOIETIN; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CELL COUNT; CELL LOSS; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; GLIA CELL; HIPPOCAMPAL CA1 REGION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN PHOSPHORYLATION; REOXYGENATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECT; FEMALE; HYPOXIA; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; ERYTHROPOIETIN; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HYPOXIA; MICE, INBRED C57BL; NEURONS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84982276912     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-0022-0     Document Type: Article

References (45)

1. Adamson JW, Eschbach J, Finch CA (1968) The kidney and erythropoiesis. Am J Med 44(5):725–733
2. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269(30):19488–19493
3. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95(8):4635–4640
4. Sanchez PE, Fares RP, Risso JJ, Bonnet C, Bouvard S, Le-Cavorsin M, Georges B, Moulin C, Belmeguenai A, Bodennec J, Morales A, Pequignot JM, Baulieu EE, Levine RA, Bezin L (2009) Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci U S A 106(24):9848–9853. doi:10.1073/pnas.0901840106
5. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, Cerami A, Probert L (2008) TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A 105(16):6185–6190. doi:10.1073/pnas.0801447105
6. Minnerup J, Heidrich J, Rogalewski A, Schabitz WR, Wellmann J (2009) The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 40(9):3113–3120. doi:10.1161/STROKEAHA.109.555789
7. Chen G, Zhang S, Shi J, Ai J, Hang C (2009) Effects of recombinant human erythropoietin (rhEPO) on JAK2/STAT3 pathway and endothelial apoptosis in the rabbit basilar artery after subarachnoid hemorrhage. Cytokine 45(3):162–168. doi:10.1016/j.cyto.2008.11.015
8. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, Calapai G, De Vico G, Piedimonte G, Salpietro FM, Tomasello F (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 99(8):5627–5631
9. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P (2008) Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 3(4):e1924. doi:10.1371/journal.pone.0001924
10. Kadota T, Shingo T, Yasuhara T, Tajiri N, Kondo A, Morimoto T, Yuan WJ, Wang F, Baba T, Tokunaga K, Miyoshi Y, Date I (2009) Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson’s disease model of rats with enhanced neurogenesis. Brain Res 1254:120–127. doi:10.1016/j.brainres.2008.11.094
11. Xue YQ, Zhao LR, Guo WP, Duan WM (2007) Intrastriatal administration of EPO protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease. Neuroscience 146(3):1245–1258
12. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681):239–242
13. Oh DH, Lee IY, Choi M, Kim SH, Son H (2012) Comparison of neurite outgrowth induced by erythropoietin (EPO) and carbamylated erythropoietin (CEPO) in hippocampal neural progenitor cells. Korean J Physiol Pharmacol 16(4):281–285. doi:10.4196/kjpp.2012.16.4.281
14. Choi M, Ko SY, Lee IY, Wang SE, Lee SH, Oh DH, Kim YS, Son H (2014) Carbamylated erythropoietin promotes neurite outgrowth and neuronal spine formation in association with CBP/p300. Biochem Biophys Res Commun 446(1):79–84. doi:10.1016/j.bbrc.2014.02.066
15. Wang L, Zhang ZG, Gregg SR, Zhang RL, Jiao Z, Letourneau Y, Liu X, Feng Y, Gerwien J, Torup L, Leist M, Noguchi CT, Chen ZY, Chopp M (2009) The sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem 282(44):32462–32470. doi:10.1074/jbc.M706880200
16. Ding J, Li QY, Yu JZ, Wang X, Lu CZ, Ma CG, Xiao BG (2013) CEPO ameliorates hypoxia-induced cognitive and behavioral defects with the generation of choline acetyltransferase-positive neurons. J Neurosci Res 91(1):73–82. doi:10.1002/jnr.23124
17. Lapchak PA, Kirkeby A, Zivin JA, Sager TN (2008) Therapeutic window for nonerythropoietic CEPO to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res 1238:208–214. doi:10.1016/j.brainres.2008.08.017
18. Fantacci M, Bianciardi P, Caretti A, Coleman TR, Cerami A, Brines M, Samaja M (2006) Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci U S A 103(46):17531–17536
19. Mahmood A, Lu D, Qu C, Goussev A, Zhang ZG, Lu C, Chopp M (2007) Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 107(2):392–397
20. Adembri C, Massagrande A, Tani A, Miranda M, Margheri M, De Gaudio R, Pellegrini-Giampietro DE (2008) Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury. Crit Care Med 36(3):975–978. doi:10.1097/CCM.0B013E3181644343
21. King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT (2007) Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 26(1):90–100
22. Millet A, Bouzat P, Trouve Buisson T, Batandier C, Pernet Gallay K, Gaide Chevronnay L, Barbier E,Debillon T, Fontaine E, Payen JF (2015) Erythropoietin and its derivates modulate mitochondrial dysfunction after diffuse traumatic brain injury. J Neurotrauma. 2015
23. Schmidt RE, Green KG, Feng D, Dorsey DA, Parvin CA, Lee JM, Xiao Q, Brines M (2008) Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 209(1):161–170
24. Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, Van Beek J, Leist M, Brines M, Cerami A, Ghezzi P (2006) Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 12(7–8):153–160
25. Thomas Tayra J, Kameda M, Yasuhara T, Agari T, Kadota T, Wang F, Kikuchi Y, Liang H, Shinko A, Wakamori T, Vcelar B, Weik R, Date I (2013) The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson’s disease. Brain Res 1502:55–70. doi:10.1016/j.brainres.2013.01.042
26. Armand-Ugón M, Aso E, Moreno J, Riera-Codina M, Sánchez A, Vegas E, Ferrer I (2014) Memory Improvement in the AβPP/PS1 mouse model of familial Alzheimer’s disease induced by carbamylated-erythropoietin is accompanied by modulation of synaptic genes. J Alzheimers Dis 29.
27. Chen J, Yang Z, Zhang X (2016) Carbamylated erythropoietin: a prospective drug candidate for neuroprotection. Biomark Insights 8(Suppl 1):25–29. doi:10.4137/BCI.S30753
28. Montero M, Poulsen FR, Noraberg J, Kirkeby A, van Beek J, Leist M, Zimmer J (2007) Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp Neurol 204(1):106–117
29. Liu W, Shen Y, Plane JM, Pleasure DE, Deng W (2011) Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol 230(2):227–239. doi:10.1016/j.expneurol.2011.04.021
30. Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H, Retnakaran R, Woo M (2010) Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 207(13):2831–2842. doi:10.1084/jem.20100665
31. Ding J, Li QY, Yu JZ, Wang X, Sun CH, Lu CZ, Xiao BG (2010) Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. Mol Cell Neurosci 43(2):201–208. doi:10.1016/j.mcn.2009.11.001
32. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, Ramos-Mejia V, Rouleau A, Yang J, Bossé M, Lajoie G, Bhatia M (2007) IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 448(7157):1015–1021
33. Prass K, Scharff A, Ruscher K, Löwl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, Meisel A (2003) Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34(8):1981–1986
34. Brines M, Cerami A (2006) Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int 70(2):246–250
35. Chung CW, Zhang QL, Qiao LY (2010) Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis. J Biol Chem 285(6):4206–4212. doi:10.1074/jbc.M109.040444
36. Xia Y, Wang CZ, Liu J, Anastasio NC, Johnson KM (2010) BDNF prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways. Neuropharmacology 58(2):330–336. doi:10.1016/j.neuropharm.2009.10.009
37. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM (1996) GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85(7):1113–1124
38. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101(41):14907–14912
39. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA (1997) The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 90(5):1867–1873
40. Fu ZQ, Shao QL, Shen JL, Zhang YJ, Zhao XX, Yao L (2010) Effect of carbamylated erythropoietin on major histocompatibility complex expression and neural differentiation of human neural stem cells. J Neuroimmunol 221(1–2):15–24. doi:10.1016/j.jneuroim.2010.01.016
41. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6(6):484–494
42. Anitha M, Gondha C, Sutliff R, Parsadanian A, Mwangi S, Sitaraman SV, Srinivasan S (2006) GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest 116(2):344–356
43. Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3(5):383–394
44. Baloh RH, Enomoto H, Johnson EJ, Milbrandt J (2000) GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol 10(1):103–110
45. Bespalov MM, Sidorova YA, Tumova S, Ahonen-Bishopp A, Magalhães AC, Kulesskiy E, Paveliev M, Rivera C, Rauvala H, Saarma M (2011) Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J Cell Biol 192(1):153–169. doi:10.1083/jcb.201009136